Abstract: AIM To evaluate the therapeutic effects and the safety of aripiprazole in the treatment of patients with schizophrenia.METHODS: 80 schizophrenic patients were randomly divided into two groups. Aripiprazole group was treated with 10-20 mg d " aripiprazole, poqd. Clozapine group was treated with clozapine 300~500 mg·d^-1, po, bid. Clinical effects were assessed with th Positive and Negative Syndrome Scale for8 weeks. Clinical effects were assessed with the Positive and Negative Syndrome Scale (PANSS), and side effects were assessed with the Treatment Emergent Symptom Scale (TESS) in following 8 weeks.RESULTS: Reduction rate in PANSS total scores in ariprazole group was 50.4%, and the efficacy was 87.5%. Reduction rate in PANSS total scoresin clozapine group was 49.4%, and the efficacy was 85%. The therapeutic effects were similar in the two groups (P > 0.05). There were some side effects such as EPS (17. 5%), headache (12. 5%), nausea and vomit-ing (10%) in aripiprazole group, but they were milderand the blood and glycometabolism was normal. Therewas no significant difference in two groups. Comparedwith the too much sedation (37.5%), secretion of paroid gland (45%), constipation (25%), gain weight(25%) in clozapine group, there was a significant differ-ence in two groups (P < 0.05 or P < 0.01).CONCLUSION: Aripiprazole is a safety and efficacy drug intreatment of patients with schizophrenia.

Key words: aripiprazole, clozapine, schizophrenia, effectiveness, compared study, random